Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD4XR3
|
|||
| Drug Name |
MB-105
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
| Company |
Mustang Bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostate stem cell antigen (PSCA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03873805) PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Mustang Bio. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.